RS Oncology

RS Oncology is a clinical-stage biotechnology company dedicated to developing innovative therapeutic solutions for patients with aggressive and metastatic cancers. Its core technology focuses on targeting PRX3, a mitochondrial protein that tumor cells rely on to neutralize high levels of reactive oxygen species and survive. By developing RSO-021, a first-in-class small molecule that irreversibly binds and inhibits mitochondrial PRX3, the company aims to induce selective cancer cell death through oxidative stress while sparing healthy tissue. This novel approach is particularly tailored for diseases characterized by high oxidative stress dependencies, including malignant pleural mesothelioma and various metastatic solid tumors.

The company’s primary clinical focus is the ongoing MITOPE study (NCT05278975), an international, multicenter Phase 1/2 clinical trial evaluating the safety, tolerability, and efficacy of RSO-021 administered intrapleurally. By targeting unique metabolic vulnerabilities within cancer cells, RS Oncology seeks to provide meaningful new treatment options for patients in relapse settings or those with limited standard-of-care alternatives. The company's multidisciplinary team of scientists and drug developers actively collaborates on global research initiatives to transition pre-clinical evidence into clinical applications, aiming to improve survival outcomes for those facing rare and late-stage cancers.